title: Erythropoietin receptor in myelodysplastic syndrome and leukemia.
abstract: Erythropoietin (Epo) is one of the main regulators of growth and differentiation of hematopoietic cells. In normal bone marrow cells, the amount of erythropoietin receptor (EpoR) was highest in the CD34+ CD38- subset, and decreased on lineage committed progenitor cells expressing CD38 antigens. Among the erythroid cells expressing GpA antigens, CD34-positive fractions expressed more EpoR than CD34-negative fractions. Although the amounts of EpoR of bone marrow cells from patients with refractory anemia (RA) were less than those of normal bone marrow cells in all phenotypes examined, there was no statistical significant difference. EpoR was detected on leukemia cells from 60% of acute myeloblastic leukemia (AML) cases and 29% of acute lymphoblastic leukemia (ALL) cases, and distributed widely among all FAB-subtypes. In spite of the presence of EpoR, in vitro proliferative response to Epo was not observed in a large proportion of AML. And there was no correlation between the amount of EpoR and the in vitro response to EPO. Patients with both EpoR expression and in vitro response to Epo had shorter remission duration than those without EpoR.
authors: Department of Medicine III, Hamamatsu University School of Medicine, Japan.
authors: Akihiro
authors: A
authors: Takeshita
authors: Kaori
authors: K
authors: Shinjo
authors: Kensuke
authors: K
authors: Naito
authors: Kazunori
authors: K
authors: Ohnishi
authors: Masato
authors: M
authors: Higuchi
authors: Ryuzo
authors: R
authors: Ohno
mesh_terms: D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D002999:Clone Cells / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000473:pathology*; D009190:Myelodysplastic Syndromes / Q000473:pathology*; D011379:Prognosis; D017467:Receptors, Erythropoietin / Q000378:metabolism* / Q000502:physiology
chemical_list: D017467:Receptors, Erythropoietin